Market research
CALA Calithera Biosciences Inc
PINK USD Financial Services
Latest close
As of 28 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1K
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- -1.54
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Financial Services
- Industry
- Shell Companies
- ISIN
- Not available
- Market cap
- 1K
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- -1.54
About
About Calithera Biosciences Inc
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Research context
Calithera Biosciences Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Financial Services
- Industry
- Shell Companies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CALA discussion.
5 years, 6 months ago
Calithera Biosciences, Inc is currently in a long term downtrend where the price is trading 39.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Calithera Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 3.9% to $-23M since the same quarter in the previous year.
Finally, its free cash flow fell by 25.2% to $-23M since the same quarter in the previous year.
Based on the above factors, Calithera Biosciences, Inc gets an overall score of 1/5.